OR WAIT 15 SECS
EMA has chosen Panalgo's Instant Health Data (IHD) platform to enable rapid analyses of real-world data.
According to a Jan. 6, 2020 press release from Panalgo, the European Medicines Agency (EMA) has chosen the Instant Health Data (IHD) platform to enable rapid analyses of real-world data.
In making its choice of IHD, EMA conducted a rigorous evaluation of several platforms, including proof-of-concept testing, in-depth hands-on analyses, and verification of results. The regulatory agency will use IHD to analyze Electronic Healthcare Data (EHDs) accessible in-house (currently data from the United Kingdom, France, and Germany) to more quickly examine drug use, assess safety/efficacy, understand how treatments perform in real-world setting, and support public health efforts in the European Union.
“We are excited to partner with EMA to support its mission of ensuring the efficacy and safety of medical products throughout the EU. Our company is strongly aligned with EMA’s public health goals, for which timely evidence-based insights are of particular importance, especially during this COVID-19 pandemic,” said Joseph Menzin, PhD, CEO of Panalgo, in the press release. “Most of Panalgo’s life sciences clients already rely on IHD to perform rapid analyses that support regulatory initiatives. The IHD platform will be a valuable tool to allow collaboration between drug manufacturers and regulatory agencies, such as EMA.”
Additionally, Panalgo has revealed the opening of its first European-based office, located in Amsterdam. Staff at the new location will support the partnership with EMA as well as the company’s growing European customer base.